Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1987 May;55(5):1121–1125. doi: 10.1128/iai.55.5.1121-1125.1987

Augmentation of endotoxin fever by recombinant human beta interferon in rabbits.

H Kawasaki, M Moriyama, A Tanaka
PMCID: PMC260478  PMID: 2437032

Abstract

Nonpyrogenic amounts of endotoxin (0.1 to 1 ng/kg), hardly detectable by conventional Limulus amoebocyte lysate tests, could produce a fever of around 1 degree C when injected with a nonpyrogenic dose (6 X 10(5) U/kg) of recombinant human beta interferon (IFN-beta) in rabbits. Release of endogenous IFN and tumor necrosis factor by endotoxin was also dramatically increased by recombinant human IFN-beta, and their levels in the blood were closely correlated with the increase of body temperature. These data suggest, if the synergism between IFN and endotoxin also operates in the homologous system (human IFN-human cells), that contaminating endotoxin in IFNs, even if not detectable by Limulus amoebocyte lysate test, can contribute to IFN fever to a considerable extent in humans.

Full text

PDF
1121

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman S. K., Hochstein H. D., Zoon K., Browne W., Rivera E., Elisberg B. Interferon fever: absence of human leukocytic pyrogen response to recombinant alpha-interferon. J Leukoc Biol. 1984 Jul;36(1):17–25. doi: 10.1002/jlb.36.1.17. [DOI] [PubMed] [Google Scholar]
  2. Arenzana-Seisdedos F., Virelizier J. L. Interferons as macrophage-activating factors. II. Enhanced secretion of interleukin 1 by lipopolysaccharide-stimulated human monocytes. Eur J Immunol. 1983 Jun;13(6):437–440. doi: 10.1002/eji.1830130602. [DOI] [PubMed] [Google Scholar]
  3. Armstrong J. A. Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol. 1981;78(Pt A):381–387. doi: 10.1016/0076-6879(81)78145-x. [DOI] [PubMed] [Google Scholar]
  4. Armstrong J. A. Semi-micro, dye-binding assay for rabbit interferon. Appl Microbiol. 1971 Apr;21(4):723–725. doi: 10.1128/am.21.4.723-725.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  6. Billiau A. Pharmacokinetic and pharmacological aspects of interferon therapy in man. Acta Microbiol Acad Sci Hung. 1981;28(3):257–262. [PubMed] [Google Scholar]
  7. Bonnem E. M., Spiegel R. J. Interferon-alpha: current status and future promise. J Biol Response Mod. 1984 Dec;3(6):580–598. [PubMed] [Google Scholar]
  8. Borg H., Lundgren E., Hollenberg M. D., Veale W. L., Tan Y. H., McPherson A. Human interferon for clinical trials: removal of pyrogen by a simple two-step procedure. Can J Physiol Pharmacol. 1981 Aug;59(8):890–892. doi: 10.1139/y81-134. [DOI] [PubMed] [Google Scholar]
  9. Candler R. V., Rouse B. T., Moore R. N. Regulation of interleukin 1 production by alpha and beta interferons: evidence for both direct and indirect enhancement. J Interferon Res. 1985 Winter;5(1):179–189. doi: 10.1089/jir.1985.5.179. [DOI] [PubMed] [Google Scholar]
  10. Desmyter J., Rawls W. E., Melnick J. L. A human interferon that crosses the species line. Proc Natl Acad Sci U S A. 1968 Jan;59(1):69–76. doi: 10.1073/pnas.59.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dinarello C. A., Bernheim H. A., Duff G. W., Le H. V., Nagabhushan T. L., Hamilton N. C., Coceani F. Mechanisms of fever induced by recombinant human interferon. J Clin Invest. 1984 Sep;74(3):906–913. doi: 10.1172/JCI111508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dinarello C. A., Cannon J. G., Wolff S. M., Bernheim H. A., Beutler B., Cerami A., Figari I. S., Palladino M. A., Jr, O'Connor J. V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1433–1450. doi: 10.1084/jem.163.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dinarello C. A. Interleukin-1. Rev Infect Dis. 1984 Jan-Feb;6(1):51–95. doi: 10.1093/clinids/6.1.51. [DOI] [PubMed] [Google Scholar]
  14. Duff G. W., Atkins E. The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with limulus amebocyte lysate gelation. J Immunol Methods. 1982 Aug 13;52(3):323–331. doi: 10.1016/0022-1759(82)90004-7. [DOI] [PubMed] [Google Scholar]
  15. Duff G. W., Durum S. K. The pyrogenic and mitogenic actions of interleukin-1 are related. Nature. 1983 Aug 4;304(5925):449–451. doi: 10.1038/304449a0. [DOI] [PubMed] [Google Scholar]
  16. Dunnick J. K., Galasso G. J. Clinical trials with exogenous interferon: summary of a meeting. J Infect Dis. 1979 Jan;139(1):109–123. doi: 10.1093/infdis/139.1.109. [DOI] [PubMed] [Google Scholar]
  17. Dunnick J. K., Galasso G. J. From the National Institute of Allergy and Infectious Diseases. Update on clinical trials with exogenous interferon. J Infect Dis. 1980 Aug;142(2):293–299. doi: 10.1093/infdis/142.2.293. [DOI] [PubMed] [Google Scholar]
  18. EICHENBERGER E., SCHMIDHAUSER-KOPP M., HURNI H., FRICSAY M., WESTPHAL O. Biologische Wirkungen eines hochgereinigten Pyrogens (Lipopolysaccharids) aus Salmonella abortus equi. Schweiz Med Wochenschr. 1955 Dec 3;85(49):1190–contd. [PubMed] [Google Scholar]
  19. Fertsch D., Vogel S. N. Recombinant interferons increase macrophage Fc receptor capacity. J Immunol. 1984 May;132(5):2436–2439. [PubMed] [Google Scholar]
  20. Gomi K., Morimoto M., Nakamizo N. Growth-inhibitory activity of recombinant human interferon-beta against cultured human cells. Gan. 1983 Oct;74(5):737–742. [PubMed] [Google Scholar]
  21. Gresser I., Bandu M. T., Brouty-boye D., Tovey M. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature. 1974 Oct 11;251(5475):543–545. doi: 10.1038/251543a0. [DOI] [PubMed] [Google Scholar]
  22. Gutterman J. U., Fine S., Quesada J., Horning S. J., Levine J. F., Alexanian R., Bernhardt L., Kramer M., Spiegel H., Colburn W. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med. 1982 May;96(5):549–556. doi: 10.7326/0003-4819-96-5-549. [DOI] [PubMed] [Google Scholar]
  23. Haranaka K., Satomi N., Sakurai A., Nariuchi H. Purification and partial amino acid sequence of rabbit tumor necrosis factor. Int J Cancer. 1985 Sep 15;36(3):395–400. [PubMed] [Google Scholar]
  24. Hashimoto H., Shibukawa N., Kojima Y. The mode of production of endotoxin-induced interferon in rabbit lymphoid cell cultures. II. Priming effect of interferon on apparently noninducible cells. Microbiol Immunol. 1979;23(10):1033–1036. doi: 10.1111/j.1348-0421.1979.tb00533.x. [DOI] [PubMed] [Google Scholar]
  25. Ingimarsson S., Cantell K., Strander H. Side effects of long-term treatment with human leukocyte interferon. J Infect Dis. 1979 Oct;140(4):560–563. doi: 10.1093/infdis/140.4.560. [DOI] [PubMed] [Google Scholar]
  26. Kuhry J. G., Poindron P., Laustriat G. Evidence for early fluidity changes in the plasma membranes of interferon treated L cells, from fluorescence anisotropy data. Biochem Biophys Res Commun. 1983 Jan 14;110(1):88–95. doi: 10.1016/0006-291x(83)91264-0. [DOI] [PubMed] [Google Scholar]
  27. Levy-Koenig R. E., Mundy M. J., Paucker K. Immunology of interferons. I. Immune response to protective and nonprotective interferons. J Immunol. 1970 Apr;104(4):785–790. [PubMed] [Google Scholar]
  28. Newton R. C. Effect of interferon on the induction of human monocyte secretion of interleukin-1 activity. Immunology. 1985 Nov;56(3):441–449. [PMC free article] [PubMed] [Google Scholar]
  29. Obayashi T., Kawai T., Tamura H., Nakahara C. New limulus amoebocyte lysate test for endotoxaemia. Lancet. 1982 Jan 30;1(8266):289–289. doi: 10.1016/s0140-6736(82)91016-9. [DOI] [PubMed] [Google Scholar]
  30. Paucker K., Dalton B. J., Ogburn C. A., Törmä E. Multiple active sites on human interferons. Proc Natl Acad Sci U S A. 1975 Nov;72(11):4587–4591. doi: 10.1073/pnas.72.11.4587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Priestman T. J. Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease. Lancet. 1980 Jul 19;2(8186):113–118. doi: 10.1016/s0140-6736(80)90004-5. [DOI] [PubMed] [Google Scholar]
  32. Ron Y., Dougherty J. P., Duff G. W., Gershon R. K. The effect of febrile temperatures on biologic actions of interferons: abrogation of suppression of delayed-type hypersensitivity and antibody production. J Immunol. 1984 Oct;133(4):2037–2042. [PubMed] [Google Scholar]
  33. Satoh M., Shimada Y., Inagawa H., Minagawa H., Kajikawa T., Oshima H., Abe S., Yamazaki M., Mizuno D. Priming effect of interferons and interleukin 2 on endogenous production of tumor necrosis factor in mice. Jpn J Cancer Res. 1986 Apr;77(4):342–344. [PubMed] [Google Scholar]
  34. Scott G. M., Wallace J., Tyrrell D. A., Cantell K., Secher D. S., Stewart W. E., 2nd Interim report on studies on "toxic" effects of human leucocyte-derived interferon-alpha (HuIFN-alpha). J Interferon Res. 1982;2(1):127–130. doi: 10.1089/jir.1982.2.127. [DOI] [PubMed] [Google Scholar]
  35. Skarnes R. C., Brown S. K., Hull S. S., McCracken J. A. Role of prostaglandin E in the biphasic fever response to endotoxin. J Exp Med. 1981 Oct 1;154(4):1212–1224. doi: 10.1084/jem.154.4.1212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Skrinska V., Lucas F. V. Isolation of prostacyclin from whole blood. Prostaglandins. 1981 Sep;22(3):365–375. doi: 10.1016/0090-6980(81)90099-x. [DOI] [PubMed] [Google Scholar]
  37. Tamura H., Obayashi T., Takagi K., Tanaka S., Nakahara C., Kawai T. Perchloric acid treatment of human blood for quantitative endotoxin assay using synthetic chromogenic substrate for horseshoe crab clotting enzyme. Thromb Res. 1982 Jul 1;27(1):51–57. doi: 10.1016/0049-3848(82)90277-8. [DOI] [PubMed] [Google Scholar]
  38. Vogel S. N., English K. E., Fertsch D., Fultz M. J. Differential modulation of macrophage membrane markers by interferon: analysis of Fc and C3b receptors, Mac-1 and Ia antigen expression. J Interferon Res. 1983;3(2):153–160. doi: 10.1089/jir.1983.3.153. [DOI] [PubMed] [Google Scholar]
  39. Williamson B. D., Carswell E. A., Rubin B. Y., Prendergast J. S., Old L. J. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5397–5401. doi: 10.1073/pnas.80.17.5397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wills R. J., Dennis S., Spiegel H. E., Gibson D. M., Nadler P. I. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther. 1984 May;35(5):722–727. doi: 10.1038/clpt.1984.101. [DOI] [PubMed] [Google Scholar]
  41. de la Maza L. M., Peterson E. M., Goebel J. M., Fennie C. W., Czarniecki C. W. Interferon-induced inhibition of Chlamydia trachomatis: dissociation from antiviral and antiproliferative effects. Infect Immun. 1985 Mar;47(3):719–722. doi: 10.1128/iai.47.3.719-722.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES